European Child and Adolescent Clinical Psychopharmacology Network (ECAPN)
The European Child & Adolescent Psychopharmacology Network (ECAPN) is a well-established network of clinical Centres of Child and Adolescent Psychiatry (currently 12), based on several EU countries, all of whom are experts in paediatric psychopharmacology.
The ECAPN has been developed as an initiative of the European Child & Adolescent Psychopharmacology Network; its’ aims include the identification of unmet needs in child and adolescent psychopharmacology, conducting collaborative scientific studies and clinical trials, and the development of strategies to improve state-of-the-art prescribing of medication to children and adolescents with psychiatric disorders in clinical practice.
The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) is a network of research networks, investigators and centres with recognised expertise in performing clinical studies in children, supported by the European Medicine Agency. Enpr-EMA's main objective is to facilitate studies in order to increase availability of medicinal products authorised for use in the paediatric population. The ECAPN Centres have a solid track record in paediatric psychopharmacology, assuring adequate experimental design, patient recruitment, biomarker definition and clinical management in large-scale studies, including formal RCTs for the registration of innovative medications. For this reason ECAPN has been recognized by Enpr-EMA as a Category 3 network.